Overview: Gemcitabine as Single-Agent Therapy for Advanced Breast Cancers
- 1 May 2002
- journal article
- review article
- Published by Elsevier BV in Clinical Breast Cancer
- Vol. 3, S8-S11
- https://doi.org/10.3816/cbc.2002.s.002
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Global cancer statisticsCA: A Cancer Journal for Clinicians, 1999
- Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women.Journal of Clinical Oncology, 1998
- Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 StudyJNCI Journal of the National Cancer Institute, 1998
- Polychemotherapy for early breast cancer: an overview of the randomised trialsThe Lancet, 1998
- Tamoxifen for early breast cancer: an overview of the randomised trialsThe Lancet, 1998
- Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.Journal of Clinical Oncology, 1997
- Modulation of deoxycytidylate deaminase in intact human leukemia cells: Action of 2',2'-difluorodeoxycytidineBiochemical Pharmacology, 1992
- A phase I clinical, plasma, and cellular pharmacology study of gemcitabine.Journal of Clinical Oncology, 1991
- 2',2'-Difluorodeoxycytidine Metabolism and Mechanism of Action In Human Leukemia CellsNucleosides, Nucleotides and Nucleic Acids, 1989
- Synthesis of 2-deoxy-2,2-difluoro-D-ribose and 2-deoxy-2,2'-difluoro-D-ribofuranosyl nucleosidesThe Journal of Organic Chemistry, 1988